Obviousness

Based on the provided authoritative text for US patent 12,264,358, the following is a technical analysis of potential obviousness arguments under 35 U.S.C. § 103.

Preliminary Caveat: Absence of Cited Prior Art and Claims

A definitive obviousness analysis requires comparing specific claim language against particular prior art references. The provided text for US patent 12,264,358 does not contain the "Claims" section, nor does it list specific prior art documents in a "References Cited" section. The only information available is a "Prior art date" of March 12, 2013, and general "Prior art keywords."

Therefore, this analysis is constructed based on the state of the art as described within the patent's own background and detailed description. It outlines the arguments a challenger would likely construct by combining known techniques that the inventors themselves acknowledge as background art.

Definition of a Person Having Ordinary Skill in the Art (PHOSITA)

A person having ordinary skill in the art (PHOSITA) at the time of the invention (around March 2013) would have had a graduate-level education (M.S. or Ph.D.) in molecular biology, biochemistry, or a related field, along with several years of laboratory experience. This individual would be well-versed in standard molecular biology techniques, including nucleic acid amplification (PCR, rolling circle amplification), in situ hybridization (ISH), microscopy (including confocal microscopy), and the principles of next-generation sequencing (NGS) platforms. A PHOSITA would also have a working knowledge of polymer chemistry, particularly the use of hydrogels like polyacrylamide for biological applications.

Potential Obviousness Combinations

The core invention of patent 12,264,358 is the in situ formation of a nucleic acid matrix that preserves the spatial location of the molecules, followed by in situ amplification and sequencing within that 3D matrix. An obviousness challenge would argue that this is a predictable combination of known elements to achieve a predictable result.

Combination 1: In Situ Amplification within a Stabilizing Hydrogel

• Prior Art A: The well-established technique of in situ amplification, such as in situ PCR or fluorescent in situ sequencing (FISSEQ), to amplify and detect nucleic acids within fixed cells or tissues. The patent's background acknowledges that identifying the location of gene products is a key goal in biology. FISSEQ, as described in the patent's detailed description (citing Mitra et al., 2003), involves amplifying and sequencing DNA in place.
• Prior Art B: The common use of porous hydrogels, particularly polyacrylamide, as a matrix for immobilizing and separating biological molecules. A PHOSITA would be intimately familiar with polyacrylamide gel electrophoresis (PAGE) and would know that these gels are permeable to enzymes, buffers, and small molecules while being capable of physically trapping larger macromolecules. The patent itself suggests polyacrylamide as a matrix material.

Motivation to Combine: A known challenge with in situ amplification techniques like in situ PCR is the potential for amplicons to diffuse from their site of origin, which degrades the spatial resolution and accuracy of the experiment. A PHOSITA would be motivated to find a way to better trap these amplicons. Combining the in situ amplification process (Art A) with a method for creating a physical, porous meshwork throughout the sample (Art B) would be an obvious solution to this diffusion problem. The patent text states, "The molecular sieve size is also chosen so that large DNA or RNA amplicons do not readily diffuse within the matrix (<500-nm)," which frames this as a predictable application of known principles of gel filtration to solve a known problem. Therefore, performing in situ amplification within a polyacrylamide gel formed in situ would have been obvious to try, with a reasonable expectation of successfully creating localized colonies of amplicons.

Combination 2: Applying Next-Generation Sequencing (NGS) Chemistries to an In Situ 3D Amplicon Matrix

• Prior Art C: The combination of A and B, resulting in a biological sample embedded in a porous hydrogel containing spatially distinct colonies of nucleic acid amplicons.
• Prior Art D: Established, commercially available NGS methods such as sequencing-by-synthesis (e.g., Illumina) and sequencing-by-ligation (e.g., ABI SoLiD). The patent explicitly describes the workflows for both platforms in its detailed description. These methods rely on iterative cycles of enzymatic reactions, washing, and fluorescence imaging performed on immobilized DNA colonies (typically on a 2D flow cell surface).

Motivation to Combine: Having created localized amplicon colonies within a 3D matrix (Art C), a PHOSITA's goal would shift from mere detection to gathering more comprehensive information, such as the actual sequence of the amplicons. It would have been an obvious next step to attempt to apply the powerful, cyclic chemistries of commercial NGS platforms (Art D) to this 3D format. Since the hydrogel in Art C is known to be permeable to the very types of reagents used in NGS (polymerases, ligases, nucleotides, buffers), adapting the fluidics to perfuse a 3D gel rather than a 2D slide would be a predictable engineering challenge. The goal—to read the sequence of the immobilized amplicons—and the proposed solution—using known sequencing chemistries—would have been obvious to a PHOSITA, who would have had a reasonable expectation of success.

Combination 3: Covalently Cross-linking Amplicons to the Matrix for Enhanced Stability

• Prior Art E: The combination of C and D, representing the process of conducting multi-cycle in situ sequencing on amplicons within a hydrogel.
• Prior Art F: The standard molecular biology practice of incorporating modified nucleotides, such as aminoallyl-dUTP, into DNA during enzymatic synthesis (e.g., PCR, reverse transcription) to introduce functional chemical groups (primary amines).
• Prior Art G: The well-known use of amine-reactive bifunctional cross-linkers, such as NHS esters (e.g., the BS(PEG)9 cross-linker explicitly used in the patent's examples), to form stable covalent bonds between molecules containing primary amines.

Motivation to Combine: A PHOSITA performing the multiple harsh chemical and thermal cycling steps required for in situ sequencing (Art E) would anticipate or quickly encounter issues with the stability of the entire construct. Amplicons could become dislodged from the matrix or unravel, leading to signal loss and positional shifts. To overcome this predictable problem of stability, the PHOSITA would turn to standard covalent immobilization strategies. The most obvious strategy would be to (1) introduce a reactive chemical handle into the amplicons during their synthesis using modified nucleotides (Art F), and (2) use a corresponding cross-linker to covalently bond these handles to each other or to a functionalized matrix (Art G). This combination is a textbook approach to biomolecule immobilization. The patent's own examples, which detail the use of aminoallyl-dUTP followed by cross-linking with BS(PEG)9, essentially describe this obvious combination, suggesting it was an application of standard tools to solve a predictable problem rather than a non-obvious leap. The resulting chemical and thermal stability, as demonstrated in FIGS. 8B and 8C, would be the expected outcome of such a covalent cross-linking strategy.